Volume 87, Issue 3, Pages (March 2015)

Slides:



Advertisements
Similar presentations
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.
Advertisements

Mineral and bone disorders in chronic kidney disease and end-stage renal disease patients: new insights into vitamin D receptor activation  Jordi Bover,
KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder.
Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward  Adeera Levin, Paul E. Stevens  Kidney International 
KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient  Christoph Wanner,
Frederik Persson, Peter Rossing  Kidney International Supplements 
Volume 74, Pages S1-S3 (August 2008)
Anemia management in chronic kidney disease
No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease  Kevin E. Chan, Ravi I. Thadhani,
KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update
Volume 83, Issue 3, Pages (March 2013)
A Decade After the KDOQI CKD Guidelines
World Kidney Day 2014: CKD and the Aging Population
Shining light on vitamin D trials in chronic kidney disease
Clinical Practice Guidelines for supplemental therapies and issues
Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007  Joanna M. Smith, Susan A. Mott,
Reassessment of the care of the patient with chronic kidney disease
C-reactive protein and dialysis access
John P. Middleton, Patrick H. Pun  Kidney International 
Clinical Practice Guidelines for supplemental therapies and issues
Volume 74, Pages S7-S11 (August 2008)
Audit-based education: a potentially effective program for improving guideline achievement in CKD patients  Moniek C.M. de Goeij, Joris I. Rotmans  Kidney.
Volume 85, Issue 3, Pages (March 2014)
Jeffrey C. Fink, Glenn M. Chertow  Kidney International 
Steven G. Coca, Swathi Singanamala, Chirag R. Parikh 
Volume 84, Issue 5, Pages (November 2013)
Comorbidity and confounding in end-stage renal disease
Volume 66, Issue 3, Pages (September 2004)
The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis  Sai Subhodhini Reddy, Jean L. Holley 
Volume 74, Issue 3, Pages (August 2008)
Volume 70, Issue 11, Pages (December 2006)
Use of vitamin D in chronic kidney disease patients
Pieter Evenepoel, Björn K. Meijers  Kidney International 
Volume 76, Pages S3-S8 (August 2009)
David Del Bello, Michael J. Ross, Shirish S. Huprikar 
Volume 73, Issue 12, Pages (June 2008)
Volume 84, Issue 4, Pages (October 2013)
Progression of polycystic kidney disease in a kidney transplant
Volume 76, Issue 6, Pages (September 2009)
A physician's perseverance uncovers problems in a key nephrology study
Evidence and Outcomes in CKD
Does reducing salt intake increase cardiovascular mortality?
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Tilman B. Drüeke, Ziad A. Massy  Kidney International 
Volume 87, Issue 3, Pages (March 2015)
Methods for guideline development
The global challenge of chronic kidney disease
Nephrology Crossword: Glomerulonephritis
A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related.
Cardiovascular risk assessment in kidney transplantation
Will there be an epidemic of HIV-related chronic kidney disease in sub-Saharan Africa? Too soon to tell  Kara K. Wools-Kaloustian, Samir K. Gupta  Kidney.
Vitamin D in chronic kidney disease: is the jury in?
Cardio-Kidney-Damage: a unifying concept
Volume 81, Issue 12, Pages (June 2012)
Volume 87, Issue 1, Pages (January 2015)
Volume 80, Issue 10, Pages (November 2011)
Volume 85, Issue 6, Pages (June 2014)
American Indian heritage and risk factors for renal injury
Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller 
Membranous nephropathy: recent travels and new roads ahead
The international realities of live donor kidney transplantation
In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression  B.O. Eriksen, O.C. Ingebretsen  Kidney.
Where vaptans do and do not fit in the treatment of hyponatremia
Volume 74, Issue 10, Pages (November 2008)
Sugar-sweetened beverages and chronic disease
Ronen Levi, Justin Silver  Kidney International 
What Should a Guideline Panel Do When Evidence Is Inconclusive
Volume 83, Issue 3, Pages (March 2013)
Presentation transcript:

Volume 87, Issue 3, Pages 502-508 (March 2015) Revisiting KDIGO clinical practice guideline on chronic kidney disease—mineral and bone disorder: a commentary from a Kidney Disease: Improving Global Outcomes controversies conference  Markus Ketteler, Grahame J. Elder, Pieter Evenepoel, Joachim H. Ix, Sophie A. Jamal, Marie-Hélène Lafage-Proust, Rukshana Shroff, Ravi I. Thadhani, Marcello A. Tonelli, Bertram L. Kasiske, David C. Wheeler, Mary B. Leonard  Kidney International  Volume 87, Issue 3, Pages 502-508 (March 2015) DOI: 10.1038/ki.2014.425 Copyright © 2015 International Society of Nephrology Terms and Conditions

Figure 1 Different potential options for updating clinical practice guidelines. A full review involves beginning guideline production from scratch, with or without retaining the existing analytical framework. A living guideline implies a document that is constantly under revision and could be revised at any point on the basis of the availability of new evidence. A selective update uses specific methods to update only those parts of the guideline in need of update (which can be quite extensive in some cases). A refresh implies a quick change to a small, circumscribed part of a guideline, without the need to assemble new multidisciplinary Work Group (e.g., new evidence necessitating an update of no more than two key questions or a policy/licensing change that would affect the whole guideline). Adapted with permission from Roberta James. Kidney International 2015 87, 502-508DOI: (10.1038/ki.2014.425) Copyright © 2015 International Society of Nephrology Terms and Conditions